Solid	B-Cancer
tumor	I-Cancer
therapy	O
:	O
manipulation	O
of	O
the	O
vasculature	B-Multi-tissue_structure
with	O
TNF	O
.	O

Drug	O
delivery	O
to	O
solid	B-Cancer
tumors	I-Cancer
is	O
one	O
of	O
the	O
most	O
challenging	O
aspects	O
in	O
cancer	B-Cancer
therapy	O
.	O

Whereas	O
agents	O
seem	O
promising	O
in	O
the	O
test	O
tube	O
,	O
clinical	O
trials	O
often	O
fail	O
due	O
to	O
unfavorable	O
pharmacokinetics	O
,	O
poor	O
delivery	O
,	O
low	O
local	O
concentrations	O
,	O
and	O
limited	O
accumulation	O
in	O
the	O
target	O
cell	B-Cell
.	O

A	O
major	O
step	O
forwards	O
in	O
the	O
treatment	O
of	O
solid	B-Cancer
tumors	I-Cancer
is	O
the	O
recognition	O
of	O
the	O
tumor	B-Cancer
-	O
associated	O
vasculature	B-Multi-tissue_structure
as	O
an	O
important	O
target	O
for	O
therapy	O
.	O

Inhibition	O
of	O
tumor	B-Multi-tissue_structure
vascular	I-Multi-tissue_structure
development	O
has	O
a	O
direct	O
effect	O
on	O
the	O
growth	O
and	O
progression	O
of	O
the	O
tumor	B-Cancer
.	O

Destruction	O
of	O
an	O
existing	O
vasculature	B-Multi-tissue_structure
also	O
directly	O
inflicts	O
serious	O
damage	O
to	O
the	O
tumor	B-Cell
cell	I-Cell
.	O

Moreover	O
,	O
the	O
tumor	B-Multi-tissue_structure
vascular	I-Multi-tissue_structure
bed	I-Multi-tissue_structure
can	O
be	O
manipulated	O
facilitating	O
enhanced	O
permissiveness	O
of	O
the	O
tumor	B-Cancer
for	O
administered	O
chemotherapeutics	O
.	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
the	O
use	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
)	O
in	O
local	O
and	O
systemic	O
therapy	O
in	O
conjunction	O
with	O
chemotherapy	O
.	O

In	O
these	O
settings	O
TNF	O
demonstrates	O
potent	O
and	O
selective	O
activity	O
on	O
the	O
tumor	B-Multi-tissue_structure
vascular	I-Multi-tissue_structure
bed	I-Multi-tissue_structure
,	O
which	O
strongly	O
improves	O
tumor	B-Cancer
response	O
.	O

